Avidity Partners Management LP Immuno Gen, Inc. Transaction History

Avidity Partners Management LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.46 - $29.95 $1.11 Million - $2.66 Million	-88,692 Reduced 4.62%	1,829,215 $54.2 Million
Q3 2023 Nov 14, 2023	SELL	$14.09 - $19.87 $1.13 Million - $1.59 Million	-79,893 Reduced 4.0%	1,917,907 $30.4 Million
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $7.49 Million - $40.1 Million	1,997,800 New	1,997,800 $37.7 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.